편평상피폐암에서 암억제유전자 RASSF1A의 메틸화와 임상 및 병리소견과의 연관성

Association between RASSF1A Methylation and Clinicopathological Factors in Patients with Squamous Cell Carcinoma of Lung

  • 최내윤 (성균관대학교 의과대학 삼성생명과학연구소 임상의학센터 암연구센터) ;
  • 이혜숙 (성균관대학교 의과대학 삼성생명과학연구소 임상의학센터 암연구센터) ;
  • 송인승 (성균관대학교 의과대학 삼성생명과학연구소 임상의학센터 암연구센터) ;
  • 임유성 (성균관대학교 의과대학 삼성생명과학연구소 임상의학센터 암연구센터) ;
  • 손대순 (성균관대학교 의과대학 삼성생명과학연구소 임상의학센터 암연구센터) ;
  • 임대식 (한국과학기술원 생명과학과) ;
  • 최용수 (성균관대학교 의과대학 흉부외과) ;
  • 김진국 (성균관대학교 의과대학 흉부외과) ;
  • 김호중 (성균관대학교 의과대학 호흡기내과)
  • Choi, Naeyun (Cancer Research Center, Center for Clinical Research, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine) ;
  • Lee, Hye-Sook (Cancer Research Center, Center for Clinical Research, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine) ;
  • Song, In Seung (Cancer Research Center, Center for Clinical Research, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine) ;
  • Lim, Yu Sung (Cancer Research Center, Center for Clinical Research, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine) ;
  • Son, Dae-Soon (Cancer Research Center, Center for Clinical Research, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine) ;
  • Lim, Dae-Sik (Department of Biological Sciences, Korea Advanced Institute of Science and Technology) ;
  • Choi, Yong Soo (Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Jhingook (Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Hojoong (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 투고 : 2004.03.03
  • 심사 : 2004.07.07
  • 발행 : 2004.09.30

초록

연구배경 : RASSF1A는 종양억제유전자 중의 하나로 폐암을 비롯한 다양한 암에서 프로모터지역의 메틸화에 의해서 발현이 억제된다. 저자들은 편평상피폐암 환자에서 RASSF1A 메틸화가 임상 및 병리소견과 어떠한 연관성을 갖는지 조사해 보고자 본 연구를 시행하였다. 방 법 : 81예의 편평상피폐암과 정상 폐조직에서 RASSF1A 메틸화를 methylation specific PCR(MSP) 방법과 염기서열 분석방법에 의해서 실험하였고, 임상 및 병리소견과의 연관성을 통계학적으로 분석하였다. 결 과 : 편평상피폐암에서 RASSF1A메틸화가 37.0%(30/81)에서 관찰되었다. RASSF1A의 메틸화는 세포분화도와 연관이 있었으며(p=0.0097), 생존율과도 연관이 있을 가능성이 있었다(p=0.0635). 그러나, RASSF1A 메틸화와 TNM 병기, 재발 유무, 임파절전이 유무, 흡연양과는 연관이 없었다. 결 론 : RASSF1A 메틸화가 편평상피폐암의 나쁜 예후와 관계 있을 것으로 생각되며, 향후 더 많은 예를 대상으로 한 연구가 필요할 것으로 사료된다.

Background : RASSF1A, which is one of tumor suppressor genes, is frequently inactivated by hypermethylation of the promoter region in a variety of human cancers, including lung cancer. This study was performed to investigate the association between RASSF1A methylation and the clinicopathological factors in patients with squamous cell carcinoma of the lung. Methods : Eighty-one samples from the patients with squamous cell carcinoma of lung were examined. The promoter methyation of RASSF1A was analyzed by methylation specific PCR and sequencing. Statistical analysis was made to examine the association between RASSF1A methylation and the clinicopathological parameters. Results : RASSF1A methylation was observed in 37.0 % (30 of 81) of the patients with squamous cell carcinoma of the lung. RASSF1A methylation was found to be associated with cellular differentiation(p=0.0097) and the overall survival(p=0.0635). However, there was no association between RASSF1A methylation and the other clinicopathological parameters, such as the pathological TNM stage, the recurrence rate, lymph node invasion and the amount of cigarettes smoked. Conclusion : RASSF1A methylation might be associated with a poor prognosis in patients with squamous carcinoma of the lung. A larger scale study is needed.

키워드

참고문헌

  1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:4-66
  2. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumours. Berlin: Springer, 1999
  3. Gazdar AF, Minna JD. Molecular detection of early lung cancer. J Natl Cancer Inst 1999;91:299-301
  4. Travis WD, Lubin J, Ries L, Deveas S. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing amongfemales. Cancer 1996;77:2464-70
  5. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplasic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000;60:1949-60
  6. Z$\ddot{o}$chbauer-Müller S, Gazdar AF, Minna JD. Molecular pathogenesis of lung cancer. Annu Rev Physiol 2002;64:681-708
  7. Kohno T, Yokota J. How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis 1999;20:1403-10
  8. Kok K, Naylor SL, Buys CHC. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 1997; 71:27-92
  9. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the residentcandidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000;60:6116-33
  10. Sekido Y, Ahmadian M, Wistuba II. Lutif F, Bader S, Wei MH, et al. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a3p21.3 tumor suppressor gene. Oncogene 1998;16:3151-7
  11. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lungtumor suppressor locus 3p21.3. Nat Genet 2000;25:315-9
  12. Burbee DG, Forgacs E, Zochbauer-Muller S, Shiva-kumar L, Fong K, Gao B, et al. Epigenetic inacti-vation of RASSF1A in lung and breast cancers andmalignant phenotype suppression. J Natl Cancer Inst 2001;93: 691-9
  13. Yu MY, Tong JH, Chan PK, Lee TL, Chan MW, Chan AW, et al. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int JCancer. 2003;105:204-9
  14. To KF, Leung WK, Lee TL, Yu J, Tong JH, Chan MW, et al. Promoter hypermethylation of tumorrelated genes in gastric intestinal metaplasia ofpatients with and without gastric cancer. Int J Cancer. 2002;102:623-8
  15. Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, Huang DP. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res. 2002;8:131-7
  16. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung,breast and ovarian tumors. Oncogene 2001;20:1509-18
  17. Dammann, R, Takahashi T, Pfeifer GP. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lungcarcinomas. Oncogene 2001;20:3563-7
  18. Tomizawa Y, Kohno T, Kondo H, Otsuka A, Nishioka M, Niki T, Yamada T, Maeshima A, Yoshimura K, Saito R, Minna JD, Yokota J. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res. 2002;8:2362-8
  19. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, Shimizu N, Shimizu K, Lee H, Chen CY, Fong KM, Gilcrease M, Roth JA, Minna JD, Gazdar AF. Smoke exposure, histologic type and geography-related differences in the methylationprofiles of non-small cell lung cancer. Int J Cancer. 2003;103:153-60
  20. Zochbauer-Muller S, Lam S, Toyooka S, Virmani AK, Toyooka KO, Seidl S, Minna JD, Gazdar AF. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer. 2003;107:612-6
  21. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, Hong HK, Lee H, Choi N, Kim J, Kim H, Kim JW, Choi EJ, Kirschner MW, Lim DS. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol. 2004;6:129-37
  22. Herman JG, Graff JR, Myohanen S, Nelkin BD Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 1996; 93: 9821-6
  23. Endoh H, Yatabe Y, Shimizu S, Tajima K, Kuwano H, Takahashi T, Mitsudomi T. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int J Cancer. 2003;106:45-51
  24. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF, Seed B, Avruch J. Identification of a novel Ras-regulated proapoptotic pathway. CurrBiol. 2002 19;12:253-65
  25. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, Avruch J. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene. 2002;21:1381-90